Algorithme Pharma gains a foothold in Europe
Canadian clinical research and bioanalysis firm Algorithme Pharma has achieved its goal of securing a European facility through its acquisition of Simbec Research in Merthyr Tydfil, Wales. This news comes only six weeks after the purchase of another clinical research centre in Baltimore, Maryland.
Canadian clinical research and bioanalysis firm Algorithme Pharma has achieved its goal of securing a European facility through its acquisition of Simbec Research in Merthyr Tydfil, Wales. This news comes only six weeks after the purchase of another clinical research centre in Baltimore, Maryland.
This latest acquisition will enable Algorithme Pharma to continue its international expansion plans, establish a foothold in Europe for the first time and, most importantly, obtain additional advanced scientific and medical expertise for its North American teams.
Simbec Research, which recently received MHRA accreditation, will continue its activities at its headquarters as a new division of Algorithme Pharma. The Simbec centre has specialised in Phase I and IIa drug development clinical trials for 30 years. The new Phase I and IIa UK location for clinical research includes a 38,000ft2 facility with 48 beds, divided into five separate research units, making it possible to carry out a number of studies simultaneously.
"Given the considerable growth of our international clientele, it became necessary to acquire a location in Europe to better serve our fast-growing market once we had expanded to the US," said Louis Caille, president and ceo of Algorithme Pharma. "The acquisition of this strategically located and highly respected clinical research centre is the first step in our European expansion strategy and provides us with an important base for future growth in the European market."